8-K: Elicio Therapeutics Announces Positive Clinical and Preclinical Data for Cancer Immunotherapies at AACR Annual Meeting

Elicio Therapeutics presented promising clinical data for ELI-002, showing strong T-cell responses and antigen spreading, and preclinical data for ELI-007 and ELI-008, demonstrating significantly enhanced immune responses compared to conventional vaccines.

Summary

• Elicio Therapeutics presented updated clinical data from its Phase 1 AMPLIFY-201 study of ELI-002, a cancer vaccine targeting mKRAS-driven cancers, at the AACR Annual Meeting.
• The data showed that 68% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD4+ T cells, and 84% developed cytotoxic mKRAS-specific CD8+ T cells.
• A majority of patients treated with ELI-002 exhibited antigen spreading, where induced T cells targeted additional patient-specific tumor mutations beyond mKRAS.
• Patients who received a booster dose of ELI-002 showed durable mKRAS-specific T cell responses with an increased memory T cell phenotype.
• Preclinical studies of ELI-007 and ELI-008, targeting BRAF and p53 mutations respectively, demonstrated a 42-fold to several-hundred-fold increase in immune response compared to conventional vaccines.
• Initial clinical data for the 7-peptide formulation of ELI-002 (ELI-002 7P) is expected to be presented in the second quarter of 2024.

Sentiment

Score: 8

Explanation: The document presents very positive clinical and preclinical data, suggesting strong potential for Elicio's cancer immunotherapies. The high T cell response rates, antigen spreading, and significant increase in immune response compared to conventional vaccines are all very encouraging.

Positives

• ELI-002 demonstrated potent immunogenicity with balanced CD4+ and CD8+ T cell responses.
• The vaccine showed HLA-agnostic activity and targeted mKRAS antigens critical for tumor survival.
• ELI-002 did not induce regulatory T cell responses, which can suppress the immune system.
• Preclinical data for ELI-007 and ELI-008 showed strong T cell activation and induction of tumor-antigen-specific T cell responses.
• The AMP technology used in the vaccines allows for direct delivery to the lymph nodes, enhancing the immune response.
• The induced T cells from ELI-007 and ELI-008 were polyfunctional, exhibiting production of multiple effector cytokines and cytotoxic molecules.

Risks

• The clinical trials are still ongoing, and the final results may differ from the presented data.
• The development of cancer immunotherapies is complex and subject to regulatory approvals.
• The success of the AMP technology in preclinical models does not guarantee similar results in human trials.
• The company's ability to advance ELI-002 outside of PDAC monotherapy and its pipeline programs is subject to various factors.

Future Outlook

Elicio expects to share interim data from the Phase 1A arm of the AMPLIFY-7P study of ELI-002 7P in the second quarter of 2024, and continues to advance its pipeline of novel immunotherapies.

Management Comments

• Christopher Haqq, M.D., Ph.D., stated that the company observed response durability and added antigen-spreading to the mechanism of ELI-002, creating a precision response that may lead to enhanced clinical activity.
• Peter DeMuth, Ph.D., noted that preclinical data demonstrates that ELI-007 and ELI-008 induce strong tumor antigen-specific T cell responses, often ten to a hundred-fold higher than comparator.

Industry Context

This announcement is significant in the context of the broader immuno-oncology field, where there is a growing focus on developing personalized cancer vaccines that can elicit strong and durable T cell responses. The use of lymph node-targeted delivery systems, like Elicio's AMP technology, is also a key area of innovation.

Comparison to Industry Standards

• The reported T cell response rates for ELI-002 are competitive with other cancer vaccine candidates in development, such as those from BioNTech and Moderna, which also target neoantigens.
• The antigen spreading observed with ELI-002 is a notable advantage, as it suggests the potential for a broader and more effective immune response against the tumor.
• The preclinical data for ELI-007 and ELI-008, showing a 42-fold to several-hundred-fold increase in immune response compared to conventional vaccines, is a significant improvement over traditional vaccine approaches.
• Companies like Gritstone bio and Immatics are also developing personalized cancer vaccines, but Elicio's AMP technology offers a unique approach to lymph node targeting.

Stakeholder Impact

• The positive data may increase investor confidence in Elicio Therapeutics.
• The potential success of the immunotherapies could benefit patients with mKRAS, BRAF, and p53-driven cancers.
• The company's employees may be motivated by the positive results and the potential to make a significant impact on cancer treatment.

Next Steps

• Elicio will continue the Phase 1 AMPLIFY-201 study of ELI-002.
• The company will present initial clinical data for the 7-peptide formulation of ELI-002 (ELI-002 7P) in the second quarter of 2024.
• Elicio will continue to develop and evaluate ELI-007 and ELI-008 in preclinical studies.

Key Dates

Keywords

immunotherapy, cancer vaccine, T cell response, antigen spreading, mKRAS, BRAF, p53, lymph node, AMP technology, clinical trial